Vanda Pharmaceuticals stock: Vanda sets October 28 results date for Vanda Pharmaceuticals stock

Published on 10/24/2026 at 04:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vanda will report third-quarter results on October 28, 2026 after market close. Analysts set a USD 20.00 target for Vanda Pharmaceuticals stock.

Dates and pipeline evidence

Vanda announced on October 21, 2026 that third-quarter results will arrive on October 28, 2026.
Second-quarter revenue reached USD 50.53 million, while GAAP loss per share was USD 1.04.
The VQW-765 study enrolled 546 adults before the program was placed on hold on October 14, 2026.
Vanda Pharmaceuticals had a USD 242.5 million market capitalization as of October 23, 2026.

VNDA, US9216591084, Illustration mit AI erstellt.

Vanda Pharmaceuticals (ISIN US9216591084) will publish its third-quarter 2026 results on October 28, 2026, after the market closes. The date was announced by PR Newswire on October 21, 2026, with a conference call scheduled for 4:30 p.m. ET.

October 28 brings the next test

The earnings date matters because Vanda enters the report with a wide gap between revenue and profitability. In the second quarter of 2026, revenue was USD 50.53 million and GAAP loss per share was USD 1.04, versus a consensus loss of USD 0.59, according to Yahoo Finance. The company posted a net loss of USD 62.51 million for that period.

The upcoming report will also be judged against the latest pipeline setback. Vanda Pharmaceuticals said on October 14, 2026 that its Phase III VQW-765 study did not meet its primary endpoint. The trial randomized 546 adults, and the program was placed on hold pending analysis of the full dataset.

What does the pipeline setback mean?

The result shifts attention toward Vanda's commercial medicines and its remaining development programs. The October 14 study recorded female-participant distress scores of 65.6 with VQW-765 and 66.0 with placebo, a difference that did not reach statistical significance. That leaves the October 28 report as the next dated opportunity to assess revenue trends, cash use and management commentary.

Three dates frame the story

Chronologically, Vanda reported USD 50.53 million of second-quarter revenue on August 5, 2026; disclosed the 546-adult VQW-765 study result on October 14, 2026; and announced the October 28, 2026 results date on October 21, 2026. Each date marks a different part of the investment case: commercial performance, pipeline risk and the next financial checkpoint.

Results and replay dates

The company will release third-quarter results after the market closes on October 28, 2026 and hold its conference call at 4:30 p.m. ET that day. PR Newswire said the call replay will begin at 8:30 p.m. ET on October 28, 2026 and remain accessible through November 4, 2026.

Market value remains small

Vanda Pharmaceuticals had a market capitalization of USD 242.5 million as of October 23, 2026, while its Nasdaq 52-week range was USD 3.88 to USD 9.94. A dated Tradegate indication stood at EUR 3.63 on October 23, 2026 at 8:02 p.m. CEST. The primary Nasdaq quote closed at USD 4.01 on October 23, 2026 at 4:00 p.m. ET, according to the market quotation.

The further course of trading is shown by the continuously updated real-time quote of Vanda Pharmaceuticals stock.